Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 114

1.

The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review.

Fossati N, Willemse PM, Van den Broeck T, van den Bergh RC, Yuan CY, Briers E, Bellmunt J, Bolla M, Cornford P, De Santis M, MacPepple E, Henry AM, Mason MD, Matveev VB, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Lam TB, Mottet N, Joniau S.

Eur Urol. 2017 Jan 24. pii: S0302-2838(16)30900-9. doi: 10.1016/j.eururo.2016.12.003. [Epub ahead of print] Review.

PMID:
28126351
2.

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N.

Eur Urol. 2016 Aug 31. pii: S0302-2838(16)30469-9. doi: 10.1016/j.eururo.2016.08.002. [Epub ahead of print]

PMID:
27591931
3.

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RC, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P.

Eur Urol. 2016 Aug 25. pii: S0302-2838(16)30470-5. doi: 10.1016/j.eururo.2016.08.003. [Epub ahead of print]

PMID:
27568654
4.

STAMPEDE trial and patients with non-metastatic prostate cancer - Authors' reply.

James ND, Sydes MR, Clarke NW, Mason MD, Parmar MK.

Lancet. 2016 Jul 16;388(10041):235-6. doi: 10.1016/S0140-6736(16)31041-8. No abstract available.

PMID:
27479566
5.

Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.

Lane A, Metcalfe C, Young GJ, Peters TJ, Blazeby J, Avery KN, Dedman D, Down L, Mason MD, Neal DE, Hamdy FC, Donovan JL; ProtecT Study group..

BJU Int. 2016 Dec;118(6):869-879. doi: 10.1111/bju.13582.

6.
7.

Prostate stromal cell proteomics analysis discriminates normal from tumour reactive stromal phenotypes.

Webber JP, Spary LK, Mason MD, Tabi Z, Brewis IA, Clayton A.

Oncotarget. 2016 Apr 12;7(15):20124-39. doi: 10.18632/oncotarget.7716.

8.
9.

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators..

Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5.

10.

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.

Vale CL, Burdett S, Rydzewska LH, Albiges L, Clarke NW, Fisher D, Fizazi K, Gravis G, James ND, Mason MD, Parmar MK, Sweeney CJ, Sydes MR, Tombal B, Tierney JF; STOpCaP Steering Group..

Lancet Oncol. 2016 Feb;17(2):243-56. doi: 10.1016/S1470-2045(15)00489-1. Review. Erratum in: Lancet Oncol. 2016 Feb;17(2):e46.

11.

Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review.

van den Bergh RC, van Casteren NJ, van den Broeck T, Fordyce ER, Gietzmann WK, Stewart F, MacLennan S, Dabestani S, Bellmunt J, Bolla M, Briers E, Cornford P, Joniau S, Mason MD, Matveev V, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Lam TB, Mottet N.

Eur Urol. 2016 May;69(5):802-20. doi: 10.1016/j.eururo.2015.11.023. Review.

PMID:
26691493
12.

Traditional Chinese medicine in the prevention and treatment of cancer and cancer metastasis.

Ye L, Jia Y, Ji KE, Sanders AJ, Xue K, Ji J, Mason MD, Jiang WG.

Oncol Lett. 2015 Sep;10(3):1240-1250.

13.

Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.

James ND, Spears MR, Clarke NW, Dearnaley DP, Mason MD, Parker CC, Ritchie AW, Russell JM, Schiavone F, Attard G, de Bono JS, Birtle A, Engeler DS, Elliott T, Matheson D, O'Sullivan J, Pudney D, Srihari N, Wallace J, Barber J, Syndikus I, Parmar MK, Sydes MR; STAMPEDE Investigators..

JAMA Oncol. 2016 Mar;2(3):348-57. doi: 10.1001/jamaoncol.2015.4350. Erratum in: JAMA Oncol. 2016 Feb;2(2):279.

14.

EPLIN: a fundamental actin regulator in cancer metastasis?

Collins RJ, Jiang WG, Hargest R, Mason MD, Sanders AJ.

Cancer Metastasis Rev. 2015 Dec;34(4):753-64. doi: 10.1007/s10555-015-9595-8. Review.

15.

YangZheng XiaoJi exerts anti-tumour growth effects by antagonising the effects of HGF and its receptor, cMET, in human lung cancer cells.

Jiang WG, Ye L, Ruge F, Owen S, Martin T, Sun PH, Sanders AJ, Lane J, Satherley L, Weeks HP, Gao Y, Wei C, Wu Y, Mason MD.

J Transl Med. 2015 Aug 27;13:280. doi: 10.1186/s12967-015-0639-1.

16.

Cardiovascular effects of hormone therapy for prostate cancer.

Lester JF, Mason MD.

Drug Healthc Patient Saf. 2015 Jul 23;7:129-38. doi: 10.2147/DHPS.S50549. Review.

17.

Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial.

Brundage M, Sydes MR, Parulekar WR, Warde P, Cowan R, Bezjak A, Kirkbride P, Parliament M, Moynihan C, Bahary JP, Parmar MK, Sanders K, Chen BE, Mason MD.

J Clin Oncol. 2015 Jul 1;33(19):2151-7. doi: 10.1200/JCO.2014.57.8724.

18.

Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14+ PD-L1+ phenotype in prostate cancer.

Spary LK, Salimu J, Webber JP, Clayton A, Mason MD, Tabi Z.

Oncoimmunology. 2014 Dec 13;3(9):e955331.

19.

Expression of Sonic Hedgehog (SHH) in human lung cancer and the impact of YangZheng XiaoJi on SHH-mediated biological function of lung cancer cells and tumor growth.

Jiang WG, Ye L, Ruge F, Sun PH, Sanders AJ, Ji K, Lane J, Zhang L, Satherley L, Weeks HP, Zhi X, Gao Y, Wei C, Wu Y, Mason MD.

Anticancer Res. 2015 Mar;35(3):1321-31.

PMID:
25750281
20.

Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer.

Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, Gospodarowicz M, Cowan R, Kostashuk EC, Anderson J, Swanson G, Parmar MK, Hayter C, Jovic G, Hiltz A, Hetherington J, Sathya J, Barber JB, McKenzie M, El-Sharkawi S, Souhami L, Hardman PD, Chen BE, Warde P.

J Clin Oncol. 2015 Jul 1;33(19):2143-50. doi: 10.1200/JCO.2014.57.7510.

Items per page

Supplemental Content

Loading ...
Support Center